Super-enhancers complexes zoom in transcription in cancer
© 2023. The Author(s)..
Super-enhancers (SEs) consist of multiple typical enhancers enriched at high density with transcription factors, histone-modifying enzymes and cofactors. Oncogenic SEs promote tumorigenesis and malignancy by altering protein-coding gene expression and noncoding regulatory element function. Therefore, they play central roles in the treatment of cancer. Here, we review the structural characteristics, organization, identification, and functions of SEs and the underlying molecular mechanism by which SEs drive oncogenic transcription in tumor cells. We then summarize abnormal SE complexes, SE-driven coding genes, and noncoding RNAs involved in tumor development. In summary, we believe that SEs show great potential as biomarkers and therapeutic targets.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Journal of experimental & clinical cancer research : CR - 42(2023), 1 vom: 28. Juli, Seite 183 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, MengTing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cofactors |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 31.07.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13046-023-02763-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360010199 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360010199 | ||
| 003 | DE-627 | ||
| 005 | 20231226082106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13046-023-02763-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM360010199 | ||
| 035 | |a (NLM)37501079 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, MengTing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Super-enhancers complexes zoom in transcription in cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 31.07.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Super-enhancers (SEs) consist of multiple typical enhancers enriched at high density with transcription factors, histone-modifying enzymes and cofactors. Oncogenic SEs promote tumorigenesis and malignancy by altering protein-coding gene expression and noncoding regulatory element function. Therefore, they play central roles in the treatment of cancer. Here, we review the structural characteristics, organization, identification, and functions of SEs and the underlying molecular mechanism by which SEs drive oncogenic transcription in tumor cells. We then summarize abnormal SE complexes, SE-driven coding genes, and noncoding RNAs involved in tumor development. In summary, we believe that SEs show great potential as biomarkers and therapeutic targets | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cofactors | |
| 650 | 4 | |a Histone-modifying enzymes | |
| 650 | 4 | |a Noncoding RNA | |
| 650 | 4 | |a Super-enhancer | |
| 650 | 4 | |a Transcription factors | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a Histones |2 NLM | |
| 700 | 1 | |a Chen, QingYang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, ShuJie |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Han |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, RuiXiang |e verfasserin |4 aut | |
| 700 | 1 | |a Xiang, YuFei |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, YanYi |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, DaSheng |e verfasserin |4 aut | |
| 700 | 1 | |a Bian, ErBao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of experimental & clinical cancer research : CR |d 1994 |g 42(2023), 1 vom: 28. Juli, Seite 183 |w (DE-627)NLM08283427X |x 1756-9966 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:1 |g day:28 |g month:07 |g pages:183 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13046-023-02763-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 1 |b 28 |c 07 |h 183 | ||